Filing identity and reporting period
The supplied filing is Caladrius Biosciences, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2020, filed May 7, 2020. This conflicts with the request metadata identifying Lisata Therapeutics and 2019 Q1; the summary below reflects the filing text, not that metadata.
Business context and key financial metrics
Caladrius is a clinical-stage biopharmaceutical company developing CD34+ cell therapies. It reported no revenue in the presented statements and incurred operating expenses to advance its clinical programs.
| Metric | Q1 2020 | Q1 2019 |
|---|---|---|
| Research and development expense | $1.499 million | $2.038 million |
| General and administrative expense | $2.558 million | $2.554 million |
| Total operating expenses / operating loss | $4.057 million | $4.592 million |
| Investment income | $71,000 | $227,000 |
| Net loss | $3.986 million | $4.365 million |
| Net loss attributable to common stockholders | $3.990 million | $4.367 million |
| Basic and diluted loss per share | $0.38 | $0.44 |
| Net cash used in operating activities | $4.241 million | $5.486 million |
At March 31, 2020, cash and cash equivalents were $20.745 million, with no marketable securities reported; working capital was approximately $16.6 million. Total assets were $22.140 million, total liabilities $5.156 million, and total stockholders’ equity $16.984 million. The filing reports operating lease liabilities of $875,000, including $339,000 current and $536,000 long-term; it does not identify borrowing debt in the presented balance sheet. Gross margin is not applicable to the reported results because no revenue is shown.
Material changes versus the prior comparable period
- Net loss narrowed by about $379,000, while operating expenses declined $535,000, or 12%. R&D fell 26%; G&A was nearly unchanged.
- Operating cash use improved by $1.245 million. Investing cash provided $11.102 million, primarily from sales of marketable securities, contributing to cash rising from $14.032 million at year-end 2019 to $20.745 million at quarter-end.
- At March 31, 2019, cash was $14.424 million, but the comparative cash-flow increase included $1.0 million in stock issuance proceeds; no such proceeds were received in Q1 2020.
Outlook, management commentary, risks and unusual items
- Management said quarter-end cash was expected to fund operating expenses for at least 12 months following issuance of the financial statements, assuming initiation of the CLBS14 Phase 3 trial depends on obtaining additional dedicated capital. The company cautioned that additional financing may not be available on acceptable terms or at all.
- After quarter-end, the company received $10.9 million net from selling a portion of its New Jersey net operating losses. On April 23, it also completed a registered direct offering and concurrent warrant placement for $5.0 million gross proceeds: 2,162,166 shares at $2.3125 per share and warrants for 1,081,083 shares exercisable at $2.25.
- CLBS14’s planned confirmatory Phase 3 study was not to begin until sufficient funding was secured; management estimated external trial costs at approximately $70 million over several years. CLBS12 enrollment in Japan had slowed amid the pandemic. Management expected a CLBS16 Phase 2b trial to start in fall 2020.
- The company had FDA authorization for an IND study of CLBS119 for COVID-19-related lung damage. COVID-19 was identified as a risk to clinical enrollment, trial sites, suppliers, transactions and access to capital; its future financial impact could not be reasonably estimated.
- CIRM funding reduced R&D expense by $0.7 million in Q1 2020; $0.9 million of funding was recorded in accrued liabilities at quarter-end. The filing reports no material adverse effect expected from pending legal matters.
- Common shares outstanding were 10,638,771 at March 31 and 12,840,403 as of May 6, 2020. The quarter-end figure excludes subsequent offering shares and potential warrant exercises.
Most important facts for investors to verify
- Confirm the issuer and period: the provided filing is Caladrius Biosciences’ Q1 2020 report, not Lisata Therapeutics’ Q1 2019 report.
- Review whether the stated 12-month cash runway incorporates the subsequent $10.9 million NOL sale and $5.0 million gross offering, and the cash needs of planned trials.
- Track actual CLBS12 enrollment and the timing and funding of CLBS16 and CLBS14 trials, including the estimated CLBS14 cost.
- Assess dilution from the April share issuance, warrants, and any further equity financing, as well as the effects of COVID-19 on operations and financing access.